Novo Nordisk Princeton Nj Novo Nordisk Princeton Nj Art
The 2020-2021 Novo Nordisk Lecture Serial
The Schoolhouse of Science is pleased to host and sponsor the TCNJ–Novo Nordisk Lecture Serial during the 2020 – 2021 academic year.
Fall 2020 Lecture
"Approaches to Healthcare: The Business Case For Being a Purpose Driven Company"
Wednesday, October vii, 2020, 11:00-12:00pm (Lecture)
Zoom link to follow
Speakers
Erin Byrne, MPH, Senior Director, Corporate Sustainability & Social Touch on, Novo Nordisk Inc.
Karin Gillespie, MBA, Manager, Brotherhood Development, Novo Nordisk Inc.
Date, Time, and Location
Wednesday, October 7, 2020
11:00am – 12:00pm – Lecture, Q&A, and Word
Zoom to link
Presentation Overview
Novo Nordisk has a stiff company purpose and focus on their Triple Lesser Line (TBL). We believe that a salubrious economy, environment, and society are fundamental to long term business success and that purpose and profit get manus in hand. Our primal contribution to society is to discover and develop innovative medicines and make them accessible to patients throughout the world. Just we know that it takes more than medicine, which is why we invest in efforts to prevent type 2 diabetes and obesity, educating healthcare professionals, offering patient support programs, and ensuring that nosotros take no negative impact on people, communities, and the surround.
In this lecture, Erin Byrne and Karin Gillespie will review the reasons backside the company maintaining a purpose driven business organization model, how it drives decision making at Novo Nordisk, and the value it creates both internally and externally. These company leaders will too get over a few specific social impact programs Novo Nordisk has in place to help patients and at-run a risk populations.
About the Speakers
Erin Byrne, MPH, Senior Managing director, Corporate Sustainability & Social Impact, Novo Nordisk Inc.
As the Senior Director of Corporate Sustainability & Social Impact, Erin manages the organization's corporate giving, sustainability, and employee appointment strategies to support the advancement of Novo Nordisk'southward Triple Bottom Line in the U.South. She works beyond all lines of business to advance the company in meeting societal needs with business solutions in a way that will be sustainable for the environment, the visitor's stakeholders and to ensure Novo Nordisk will be in business organisation to serve future generations.
Erin has been with Novo Nordisk for 14 years and has held diverse roles within the organization including sales, patient advancement, concern strategy, and Public Affairs. She also is currently responsible for managing Novo Nordisk'southward relationship with the Danish Ministry of Foreign Diplomacy in the U.Southward.
Prior to working at Novo Nordisk she was a pharmaceutical sales representative at Johnson & Johnson. She holds a BA in Communication from Rutgers University and an MPH in nutrition from New York Academy (NYU). She lives in Bucks Canton, PA with her husband, 3 children, and their Boston terrier.
Karin B. Gillespie, MBA, Director, Alliance Development, Novo Nordisk Inc.
Karin Gillespie is Director of Alliance Development at Novo Nordisk Inc. (NNI) within the Public Affairs function. She is the U.Due south. Projection Atomic number 82 for Cities Changing Diabetes, a global program focused on addressing diabetes in urban settings through better understanding of community-level vulnerability and crowd-sourcing solutions with customs stakeholders. Every bit such, she has worked with stakeholders that include employers, public health departments, health plans, health systems, professional person and provider associations, and customs- and organized religion-based organizations in Houston, Texas since 2014 to develop and implement solutions to address the diabetes problem in the urban center. This work has received a number of awards including the Public Affairs Council honor for Stakeholder Engagement in 2017 and Houston'south Stella Trimble Community Service Award. Karin is at present leading an attempt to take Cities Irresolute Diabetes to Philadelphia as the second city in the U.S.
Karin also serves every bit co-chair for the Diabetes Advocacy Alliance (DAA), a 24-member coalition of patient, professional person and trade associations, other nonprofit organizations, and corporations. In her work with the DAA, Karin led the efforts of Novo Nordisk Inc. to accelerate a meliorate federal diabetes screening guideline, which included hosting policy roundtables, building the evidence base, engaging with federal agencies and members of Congress, and developing advocacy materials. Karin also led a Novo Nordisk Inc. grant to Y-USA to aid advance Medicare coverage of the Diabetes Prevention Plan through a multi-site pilot.
Karin has a BA from Princeton University and an MBA in Health Care Management from The Wharton School.
Leap 2021 Lecture
"Understanding NASH as a Metabolic Disease"
Wednesday, March 24, 2021, 12:15 pm
Zoom link to follow
Speaker
Dr. Amy Articolo, Exercise, FACOG, Dipl. of ABOM, Medical Director-NASH Program, Novo Nordisk Inc.
Presentation Overview
NonAlcoholic SteatoHepatitis – otherwise known equally NASH – is a chronic disease affecting v -half-dozen% of the general population yet in that location are no underlying medical treatments approved to treat the illness. Dr. Amy Articolo from Novo Nordisk will review the details of the disease, the primary underlying conditions of NASH, why it is a metabolic disease, and the current guidelines for handling.
About the Speaker
Amy Articolo, DO, FACOG, Dipl. of ABOM graduated from the Philadelphia Higher of Osteopathic Medicine and is board-certified in Obstetrics and Gynecology and Obesity Medicine. Get-go a practicing obstetrician/gynecologist, she expanded her scope of intendance to becoming co-possessor and medical director of the Salevo Weight Management Middle, which focused on the chronic care treatment of the bariatric patient. Her dedication to obesity direction and education has ed her to get a long-time counselor and consultant for Novo Nordisk, where she is currently the Medical Managing director for their Non-Alcoholic Steatohepatits (NASH) program, leading the medical, strategic, scientific, and operational expertise in the planning and execution of medical diplomacy in NASH. As a lath member, Dr. Articolo has likewise contributed her time and expertise to a number of charitable organizations, including the Franklin Foundation for Innovation and the Obesity Treatment Foundation.
TCNJ–Novo Nordisk Educatee Scholarships
In add-on to sponsoring the Lecture Series, Novo Nordisk will support multiple scholarships for the 2021-2022 academic year. These scholarships will be competitively awarded to students who take attended the TCNJ–Novo Nordisk lectures during the 2020-2021 bookish year and who have been deeply engaged in undergraduate research.
Student Eligibility and Application
Eligible students will include those in their Sophomore or Junior years who are pursuing a major in the School of Science. These students should have (i) attended at least one, just preferably both, of the Novo Nordisk lectures during the 2020-2021 academic year, (2) been securely engaged in undergraduate research or a research-based internship, and (3) presented their work in a formal on-campus or off-campus professional person setting (e.g., TCNJ'southward Celebration of Educatee Achievement, a professional conference).
Eligible students will be invited to complete an application, which volition include (a) demographic and academic information (e.grand., academic major, year in the college, grade point average, etc.), (b) an essay on what they learned from participation in the TCNJ–Novo Nordisk lectures and how this connects with their coursework and/or signature experience piece of work, (c) an essay on what they have learned from their signature experience work, and (d) an essay describing their aspirations and plans for pursuing their career. The four awardees will be competitively selected by a group of TCNJ faculty members.
TCNJ–Novo Nordisk Summer Research Fellowship
Novo Nordisk will also back up TCNJ'south summertime 2021 MUSE program, or Thouentored Undergraduate Research Feel. Students interested in the MUSE programme should discuss the program and summertime opportunities with their kinesthesia advisor.
Virtually Novo Nordisk
Headquartered in Kingdom of denmark, Novo Nordisk is a global healthcare company with more than than ninety years of innovation and leadership in diabetes care. The company also has leading positions inside haemophilia care, growth hormone therapy, and hormone replacement therapy.
With the company's U.S. headquarters located in Plainsboro, NJ, Novo Nordisk has long been committed to establishing programs throughout the Garden State that strive to make an impact in our local communities. The TCNJ–Novo Nordisk Lecture Series, initiated in 2015-2016, is an exciting collaboration that provides students and faculty with the unique opportunity to larn and engage in a dialog with company leaders representing a variety of disciplines.
For More Information:
- Novo Nordisk
- 2015-2016 TCNJ-Novo Nordisk Lecture Series
- 2017-2018 TCNJ-Novo Nordisk Lecture Series
- 2018-2019 TCNJ-Novo Nordisk Lecture Series
- 2019-2020 TCNJ-Novo Nordisk Lecture Series
- Celebration of Student Achievement
- School of Scientific discipline
Source: https://science.tcnj.edu/2020/09/22/the-2020-2021-novo-nordisk-lecture-series/
Post a Comment for "Novo Nordisk Princeton Nj Novo Nordisk Princeton Nj Art"